Nasdaq Kros News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Nasdaq kros. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Nasdaq Kros Today - Breaking & Trending Today

Keros Therapeutics' (KROS) Overweight Rating Reiterated at Piper Sandler

Piper Sandler reissued their overweight rating on shares of Keros Therapeutics (NASDAQ:KROS – Free Report) in a report issued on Wednesday, Benzinga reports. They currently have a $105.00 price objective on the stock. Several other equities research analysts have also issued reports on the stock. Wedbush reaffirmed an outperform rating and issued a $86.00 price […] ....

United States , Piper Sandler , William Blair , Vanguard Group Inc , Goldman Sachs Group Inc , Blue Owl Capital Holdings , Keros Therapeutics Inc , Keros Therapeutics Company Profile , Barclays Plc , Wells Fargo Company , Keros Therapeutics , Free Report , Get Free Report , Sachs Group , Owl Capital Holdings , Keros Therapeutics Daily , Nasdaq Kros , Reiterated Rating ,

Keros Therapeutics, Inc. (NASDAQ:KROS) Given Consensus Rating of "Buy" by Analysts

Keros Therapeutics, Inc. (NASDAQ:KROS – Get Free Report) has been assigned a consensus recommendation of “Buy” from the four analysts that are covering the stock, Marketbeat reports. Four investment analysts have rated the stock with a buy rating. The average 12-month price target among brokerages that have updated their coverage on the stock in the […] ....

United States , Wells Fargo Company , Metlife Investment Management , Keros Therapeutics Inc , Jpmorgan Chase Co , Blackrock Inc , Keros Therapeutics , Get Free Report , Therapeutics Stock Down , Life Investment Management , Allianz Asset Management Gmbh , Asset Management Gmbh , Get Free , Keros Therapeutics Daily , Nasdaq Kros ,

Keros Therapeutics (NASDAQ:KROS) Research Coverage Started at Wells Fargo & Company

Wells Fargo & Company assumed coverage on shares of Keros Therapeutics (NASDAQ:KROS – Free Report) in a research report report published on Friday morning, MarketBeat Ratings reports. The firm issued an overweight rating and a $60.00 target price on the stock. Separately, Wedbush reiterated an outperform rating and issued a $86.00 price objective on shares […] ....

New Zealand General , New Zealand , United States , Wellington Management Group , Keros Therapeutics Inc , Keros Therapeutics Company Profile , Wells Fargo Company , Wells Fargo , Keros Therapeutics , Free Report , Marketbeat Ratings , Therapeutics Stock Down , Get Free Report , Management Group , Retirement System , State Teachers Retirement System , Amalgamated Bank , Keros Therapeutics Daily , Nasdaq Kros , Initiated Coverage , Wells Fargo Amp Company ,

Keros Therapeutics, Inc. (NASDAQ:KROS) Receives $93.20 Average Price Target from Brokerages

Keros Therapeutics, Inc. (NASDAQ:KROS – Get Free Report) has been assigned a consensus rating of “Buy” from the six research firms that are presently covering the stock, Marketbeat.com reports. Six equities research analysts have rated the stock with a buy recommendation. The average 1-year price objective among brokers that have issued ratings on the stock […] ....

United States , Hong Kong , Almanack Investment Partners , Keros Therapeutics Inc , Tower Research Capital , Osaic Holdings Inc , Hong Kong Ltd , Meitav Investment House Ltd , Keros Therapeutics , Get Free Report , Kong Ltd , Investment Partners , Research Capital , Meitav Investment House , Get Free , Keros Therapeutics Daily , Nasdaq Kros ,